The case for chemoprevention as a tool to avert breast cancer
OBG Management. 2009 July;21(07):44-52
July 1, 2009|OBG Management
Author and Disclosure Information
Women at high risk of invasive breast cancer can elect chemoprevention with tamoxifen or raloxifene. An aromatase inhibitor may one day be an option.
IN THIS ARTICLE
The main drawback of these agents—besides the fact that they are not FDA-approved for reducing risk—is their antiestrogenic effect on bone and lipid metabolism. They also induce vasomotor symptoms.
Studies of third-generation aromatase inhibitors in the prevention of breast cancer are under way in high-risk women. These agents include anastrozole, exemestane, and letrozole.
